Antibiotic Treatment for Purulent Skin Infections in Dialysis Patients

Initial Assessment and Treatment Approach

• Purulent skin and soft tissue infections (SSTIs) in dialysis patients require prompt antimicrobial therapy with careful consideration of renal function, and incision and drainage is indicated for all purulent SSTIs as the primary intervention, with antibiotic therapy added based on severity, considering systemic signs of infection 1

First-Line Antibiotic Recommendations

• The Infectious Diseases Society of America recommends that purulent skin and soft tissue infections in dialysis patients require prompt antimicrobial therapy with careful consideration of renal function, and other options include sulfamethoxazole-trimethoprim or doxycycline if the patient has confirmed MRSA 1

Alternative Options for MRSA Coverage

• If MRSA is suspected or confirmed, daptomycin or linezolid are preferred over vancomycin, with daptomycin dosed at 6 mg/kg after each dialysis session, and oral linezolid 600 mg every 12 hours can be used for MRSA coverage in dialysis patients 2, 3

Treatment Duration and Monitoring

• For uncomplicated purulent skin infections, a 7-day antibiotic regimen is typically sufficient, and for dialysis catheter-related infections, longer courses (4-6 weeks) may be needed for persistent bacteremia or complications, with monitoring for clinical improvement within 48-72 hours of initiating therapy 1, 3
• Surveillance blood cultures should be obtained 1 week after completion of antibiotics if a dialysis catheter has been retained 3

Special Considerations

• For polymicrobial infections, which may be more common in dialysis patients, combination therapy with gram-negative coverage may be needed, and for severe infections or sepsis, consider vancomycin plus piperacillin/tazobactam initially until culture results are available 1
• Never delay incision and drainage when indicated, as this is a crucial component of treatment for purulent infections 1